• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BMS/AstraZeneca Diabetes Drug Saxagliptin Hits Mark

BMS/AstraZeneca Diabetes Drug Saxagliptin Hits Mark

June 17, 2008
CenterWatch Staff

Bristol-Myers Squibb and AstraZeneca reported positive results from a phase III, pivotal trial of saxagliptin (Onglyza) for the treatment of type 2 diabetes. Saxagliptin could rival Merck’s newest diabetes drug, Januvia. The global diabetes treatment market is $23 billion, according to data from IMS Health.

AstraZeneca reportedly paid BMS $100 million upfront and up to $950 million more in milestones in a partnership develop two investigational drugs for the diabetes. AstraZeneca agreed to take on 75% of the development costs of both compounds, including saxagliptin –- a dipeptidyl peptidase-4 (DPP-4) inhibitor completing phase III – and dapagliflozin (BMS-512148),  a sodium-glucose cotransporter-2 (SGLT2) inhibitor in phase IIb. 

The companies stated they will share global sales and revenue on both products. In December 2006, BMS granted Otsuka Pharmaceutical exclusive rights in Japan to develop and commercialize saxagliptin for type 2 diabetes.*

Saxagliptin is being developed to improve the timing of insulin release thus decreasing high blood sugar.

The trial was set up as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled 401 treatment-naïve subjects.

Subjects were randomized to one of four separate treatment arms: saxagliptin 2.5 mg, 5 mg or 10 mg or placebo, once daily. The primary endpoint was the change from baseline to Week 24 in glycosylated hemoglobin level (A1C).

The secondary endpoints of the study included achievement of A1C of less than 7% and changes from baseline in fasting plasma glucose (FPG). Saxagliptin 2.5 mg, 5 mg and 10 mg demonstrated a significant mean change in A1C from baseline of -0.4%, -0.5% and -0.5%, respectively, resulting in a placebo-adjusted change of -0.6%, -0.6% and -0.7%, respectively (p-value less than 0.0001).

Reductions in A1C levels were seen as early as four weeks after initiation of saxagliptin treatment, the first scheduled A1C measurement point.A1C of less than 7% at Week 24 was observed in 35%, 38% and 41% of subjects in the saxagliptin 2.5 mg, 5 mg and 10 mg arms, respectively, compared with 24% of individuals treated with placebo (p-value not significant at the 2.5 mg dose; p-value at the other doses less than 0.05).

Treatment was well tolerated; over 24 weeks saxagliptin had an adverse event profile similar to placebo. The drug was not associated with weight gain in any of the treatment groups.

Based on the results, BMS and AstraZeneca plan to submit a new drug application (NDA) in the U.S. in mid 2008.

* Updated: CTToday previously reported that Takeda Pharmaceutical owned the Japanese rights to saxagliptin, in fact it does not. As stated above, Otsuka Pharmaceutical owns those rights.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing